Cogent Biosciences (COGT) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

COGT Stock Forecast


Cogent Biosciences stock forecast is as follows: an average price target of $18.83 (represents a 58.64% upside from COGT’s last price of $11.87) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

COGT Price Target


The average price target for Cogent Biosciences (COGT) is $18.83 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $24.00 to $15.00. This represents a potential 58.64% upside from COGT's last price of $11.87.

COGT Analyst Ratings


Buy

According to 6 Wall Street analysts, Cogent Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for COGT stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Cogent Biosciences Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 24, 2024David LebowitzCitigroup$15.00$10.6540.85%26.37%
Sep 03, 2024David LebowitzCitigroup$13.00$10.9518.72%9.52%
Sep 03, 2024Robert BurnsH.C. Wainwright$17.00$11.3749.52%43.22%
Mar 30, 2024Kelly ShiJefferies$20.00$6.72197.62%68.49%
Dec 14, 2022-Needham$24.00$12.3294.81%102.19%
Jun 17, 2022Chris RaymondRaymond James$22.00$9.19139.39%85.34%
Jun 10, 2022Christopher LiuLeerink Partners$15.00$10.7439.66%26.37%
Row per page
Go to

The latest Cogent Biosciences stock forecast, released on Sep 24, 2024 by David Lebowitz from Citigroup, set a price target of $15.00, which represents a 40.85% increase from the stock price at the time of the forecast ($10.65), and a 26.37% increase from COGT last price ($11.87).

Cogent Biosciences Price Target by Period


1M3M12M
# Anlaysts-34
Avg Price Target-$15.00$16.25
Last Closing Price$11.87$11.87$11.87
Upside/Downside-100.00%26.37%36.90%

In the current month, the average price target of Cogent Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cogent Biosciences's last price of $11.87. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Sep 24, 2024CitigroupBuyBuyHold
Sep 03, 2024CitigroupBuyBuyHold
Sep 03, 2024Piper SandlerOverweightOverweightHold
Sep 03, 2024H.C. WainwrightBuyBuyHold
May 24, 2024Piper SandlerOverweightOverweightHold
Dec 14, 2022Needham-BuyInitialise
Dec 13, 2022GuggenheimBuyBuyHold
Jun 17, 2022Piper SandlerOverweightOverweightHold
Jun 10, 2022SVB LeerinkOutperformOutperformHold
Row per page
Go to

Cogent Biosciences's last stock rating was published by Citigroup on Sep 24, 2024. The company gave COGT a "Buy" rating, the same as its previous rate.

Cogent Biosciences Financial Forecast


Cogent Biosciences Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18
Revenue--------$7.03M$15.29M$1.02M$3.14M$3.05M$2.22M
Avg Forecast$1.68M$1.09M$588.63K$179.93K---$50.00K$2.00M$3.74M$3.52M$3.25M$3.11M$2.06M
High Forecast$1.68M$1.09M$588.63K$179.93K---$50.00K$2.00M$3.74M$3.52M$3.25M$3.11M$2.47M
Low Forecast$1.68M$1.09M$588.63K$179.93K---$50.00K$2.00M$3.74M$3.52M$3.25M$3.11M$1.65M
# Analysts1111---1398610614
Surprise %-------0.00%3.52%4.08%0.29%0.97%0.98%1.08%

Cogent Biosciences's average Quarter revenue forecast for Jun 24 based on 0 analysts is -, with a low forecast of -, and a high forecast of -. COGT's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of - (Dec 20).

Cogent Biosciences EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18
# Analysts1111---1398610614
EBITDA-------$-11.32M$-5.80M$2.61M$-11.61M$-10.19M$-11.36M$-6.42M
Avg Forecast$335.82K$217.17K$117.73K$35.99K---$10.00K$-7.83M$748.80K$704.93K$649.45K$-9.40M$-5.92M
High Forecast$335.82K$217.17K$117.73K$35.99K---$10.00K$-6.26M$748.80K$704.93K$649.45K$-7.52M$-4.74M
Low Forecast$335.82K$217.17K$117.73K$35.99K---$10.00K$-9.39M$748.80K$704.93K$649.45K$-11.28M$-7.11M
Surprise %--------1132.21%0.74%3.49%-16.46%-15.68%1.21%1.08%

9 analysts predict COGT's average Quarter EBITDA for Mar 20 to be $-7.83M, with a high of $-6.26M and a low of $-9.39M. This is -399.74% lower than Cogent Biosciences's previous annual EBITDA (Dec 19) of $2.61M.

Cogent Biosciences Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18
# Analysts1111---1398610614
Net Income-------$-11.34M$-6.09M$2.30M$-11.92M$-10.52M$-11.69M$-6.74M
Avg Forecast$-55.06M$-54.35M$-53.40M$-53.29M$-56.47M$-56.19M$-55.28M$-50.61M$-8.22M$-107.18M$-123.06M$-153.23M$-9.67M$-6.21M
High Forecast$-55.06M$-54.35M$-53.40M$-53.29M$-56.47M$-44.95M$-55.28M$-50.61M$-6.58M$-107.18M$-123.06M$-153.23M$-7.74M$-4.97M
Low Forecast$-55.06M$-54.35M$-53.40M$-53.29M$-56.47M$-68.45M$-55.28M$-50.61M$-9.87M$-107.18M$-123.06M$-153.23M$-11.60M$-7.46M
Surprise %-------0.22%0.74%-0.02%0.10%0.07%1.21%1.08%

Cogent Biosciences's average Quarter net income forecast for Mar 20 is $-8.22M, with a range of $-9.87M to $-6.58M. COGT's average Quarter net income forecast represents a -458.05% decrease compared to the company's last Quarter net income of $2.30M (Dec 19).

Cogent Biosciences SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18
# Analysts1111---1398610614
SG&A-------$5.35M$3.67M$2.69M$2.72M$3.06M$2.49M$1.06M
Avg Forecast$1.91M$1.24M$671.15K$205.16K---$57.01K$2.28M$4.27M$4.02M$3.70M$2.06M$981.60K
High Forecast$1.91M$1.24M$671.15K$205.16K---$57.01K$2.28M$4.27M$4.02M$3.70M$2.47M$1.18M
Low Forecast$1.91M$1.24M$671.15K$205.16K---$57.01K$2.28M$4.27M$4.02M$3.70M$1.65M$785.28K
Surprise %-------93.81%1.61%0.63%0.68%0.83%1.21%1.08%

Cogent Biosciences's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to COGT last annual SG&A of $5.35M (Dec 20).

Cogent Biosciences EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Dec 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18
# Analysts1111---1398610614
EPS-------$-0.59$-0.80$0.28$-1.56$-1.36$-1.56$-2.64
Avg Forecast$-0.55$-0.55$-0.54$-0.54$-0.57$-0.57$-0.56$-0.51$-1.20$-1.08$-1.24$-1.54$-1.28$-0.33
High Forecast$-0.55$-0.55$-0.54$-0.54$-0.57$-0.45$-0.56$-0.51$-1.20$-1.08$-1.24$-1.54$-1.28$-0.27
Low Forecast$-0.55$-0.55$-0.54$-0.54$-0.57$-0.69$-0.56$-0.51$-1.20$-1.08$-1.24$-1.54$-1.28$-0.40
Surprise %-------1.16%0.67%-0.26%1.26%0.88%1.22%8.00%

According to 9 Wall Street analysts, Cogent Biosciences's projected average Quarter EPS for Mar 20 is $-1.20, with a low estimate of $-1.20 and a high estimate of $-1.20. This represents a -528.57% decrease compared to COGT previous annual EPS of $0.28 (Dec 19).

Cogent Biosciences Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
VTYXVentyx Biosciences$2.15$33.861474.88%Buy
ZNTLZentalis Pharmaceuticals$3.73$21.86486.06%Buy
LIFEaTyr Pharma$1.90$11.00478.95%Buy
SANASana Bio$3.76$12.00219.15%Buy
FIXXQ32 Bio$0.93$2.70190.32%Buy
LRMRLarimar Therapeutics$7.57$20.33168.56%Buy
ANABAnaptysBio$19.94$52.33162.44%Buy
OLMAOlema Pharmaceuticals$11.86$28.50140.30%Buy
KALVKalVista Pharmaceuticals$11.63$26.00123.56%Buy
CGEMCullinan Oncology$15.92$31.5097.86%Buy
SNDXSyndax Pharmaceuticals$18.94$36.1190.65%Buy
KROSKeros Therapeutics$59.95$102.0070.14%Buy
KNSAKiniksa Pharmaceuticals$21.48$36.3369.13%Buy
MRSNMersana Therapeutics$1.84$3.0063.04%Buy
IDYAIDEAYA Biosciences$30.00$48.3661.20%Buy
COGTCogent Biosciences$11.87$18.8358.64%Buy
MGTXMeiraGTx$5.96$9.0051.01%Buy
KURAKura Oncology$17.81$26.0045.99%Buy
PTGXProtagonist Therapeutics$46.76$50.006.93%Buy
VRNAVerona Pharma$38.15$33.00-13.50%Buy
CERECerevel Therapeutics$44.96$33.50-25.49%Buy

COGT Forecast FAQ


Yes, according to 6 Wall Street analysts, Cogent Biosciences (COGT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of COGT's total ratings.

Cogent Biosciences (COGT) average price target is $18.83 with a range of $15 to $24, implying a 58.64% from its last price of $11.87. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for COGT stock, the company can go up by 58.64% (from the last price of $11.87 to the average price target of $18.83), up by 102.19% based on the highest stock price target, and up by 26.37% based on the lowest stock price target.

COGT's highest twelve months analyst stock price target of $24 supports the claim that Cogent Biosciences can reach $20 in the near future.

Cogent Biosciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-168M (high $-157M, low $-180M), average SG&A $0 (high $0, low $0), and average EPS is $-1.692 (high $-1.579, low $-1.816). COGT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.53M (high $3.53M, low $3.53M), average EBITDA is $706.7K (high $706.7K, low $706.7K), average net income is $-216M (high $-216M, low $-216M), average SG&A $4.03M (high $4.03M, low $4.03M), and average EPS is $-2.177 (high $-2.177, low $-2.177).

Based on Cogent Biosciences's last annual report (Dec 2020), the company's revenue was $7.87M, beating the average analysts forecast of $2.05M by 283.95%. Apple's EBITDA was $-89.692M, beating the average prediction of $-7.816M by 1047.50%. The company's net income was $-59.204M, beating the average estimation of $-58.837M by 0.62%. Apple's SG&A was $17.42M, beating the average forecast of $2.34M by 645.36%. Lastly, the company's EPS was $-5.34, beating the average prediction of $-1.71 by 212.28%. In terms of the last quarterly report (Dec 2020), Cogent Biosciences's revenue was $0.000008, missing the average analysts' forecast of $50K by -100.00%. The company's EBITDA was $-11.321M, missing the average prediction of $10K by -113321.32%. Cogent Biosciences's net income was $-11.338M, missing the average estimation of $-50.612M by -77.60%. The company's SG&A was $5.35M, beating the average forecast of $57.01K by 9280.97%. Lastly, the company's EPS was $-0.594, beating the average prediction of $-0.51 by 16.47%